FDA approves Kebilidi for aromatic L-amino acid decarboxylase deficiency

The U.S. Food and Drug Administration has approved PTC Therapeutics’ Kebilidi (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup